Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases.
Sheheryar K KabrajiJing NiSarah L SammonsTianyu LiAmanda E D Van SwearingenYanzhi WangAlyssa M PeresleteLiangge HsuPamela J DiPiroChristopher D LascolaHeather B MooreMelissa E HughesAkshara Singareeka RaghavendraMaria K Gule-MonroeRashmi K MurthyEric P WinerCarey K AndersJean J ZhaoNancy U LinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
T-DXd demonstrates evidence of CNS activity in HER2-positive and HER2-low PDX models of BCBM and preliminary evidence of clinical efficacy in a multi-institution case series of patients with BCBM. Prospective clinical trials to further evaluate CNS activity of T-DXd in patients with active brain metastases are warranted.